Table 2.
Compliance of blood sampling, follow-up and MDA coverages
| Characteristics | Baseline | Follow-up time | ||||||
|---|---|---|---|---|---|---|---|---|
| M0 (MDA1) | M1 (MDA2) | M2 (MDA3) | M3 | M6 | M9 | M12 | Overallb | |
| Number of villagers in village during the surveya | ||||||||
| Intervention village (early MDA) | 1036 | 1036 | 1036 | 1029 | 1012 | 1022 | 1022 | 1073 |
| Control village (deferred MDA) | 883 | 889 | 877 | 879 | 899 | 936 | ||
| Blood sampling coverage, n (%) | ||||||||
| Intervention village (early MDA) | 879 (85) | 745 (72%) | 801 (79%) | 792 (77%) | 808 (79%) | 948 (88%) | ||
| Control village (deferred MDA) | 803 (91) | 722 (81%) | 655 (75%) | 618 (70%) | 689 (77%) | 875 (93%) | ||
| p-value | < 0.001 | |||||||
| MDA coverage in intervention village, n (%) | ||||||||
| Not received MDA | 194 (19.0) | 205 (19.8) | 187 (18.0) | |||||
| Not completed MDA | 20 (2.0) | 10 (1.0) | 6 (0.6) | |||||
| Completed 3 days MDA | 822 (79.3) | 821 (79.2) | 843 (81.3) | |||||
| People who took any dose in 3 rounds, n (%) | 872 (84) | |||||||
| Completed 3 rounds (9 doses) | 781 (90) | |||||||
aExcluded people away
bAt least participated once